A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights ...
The top content from the World Conference on Lung Cancer (WCLC) 2025 highlighted panels and abstracts presented during the ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
The efficacy and toxicity of osimertinib in T790M-positive NSCLC with acquired resistance to EGFR-TKI in clinical practice. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...
According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer. Certain features may make patients ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
ESMO: Blueprint preps trial of drug targeting triple-mutant EGFR in lung cancer backed by mouse data
AstraZeneca’s targeted drug Tagrisso is a go-to for treating non-small cell lung cancer (NSCLC) patients whose tumors harbor mutations in the gene EGFR. But patients invariably become resistant to the ...
Roman Perez-Soler, M.D. discusses the EGFR resistance in non-small cell lung cancer (NSCLC). There may be some good news on the horizon for patients with non-small cell lung cancer (NSCLC) who are ...
Please provide your email address to receive an email when new articles are posted on . Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback